Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Parallel Assigned, Open-label Study to Investigate the Efficacy and Safety of Yimitasvir Phosphate (DAG181)/Sofosbuvir(SOF) Combination for 12 Weeks in Subjects With Chronic Genotype 1 HCV Infection

NCT03458481 is registered in ClinicalTrials.gov with Sunshine Lake Pharma Co., Ltd. as lead sponsor.

NCT NCT03458481
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03458481 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Parallel Assigned, Open-label Study to Investigate the Efficacy and Safety of Yimitasvir Phosphate (DAG181)/Sofosbuvir(SOF) Combination for 12 Weeks in Subjects With Chronic Genotype 1 HCV Infection
Lead sponsor
Sunshine Lake Pharma Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2017
Completion date
September 26, 2018
Enrollment
129 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hcv infection